These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 10976021

  • 21. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F, Akarca US, Ersöz G, Karasu Z, Yüce G, Batur Y.
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Survival algorithms and outcome analysis in primary biliary cirrhosis.
    Pasha TM, Dickson ER.
    Semin Liver Dis; 1997 May; 17(2):147-58. PubMed ID: 9170202
    [Abstract] [Full Text] [Related]

  • 26. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF.
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [Abstract] [Full Text] [Related]

  • 27. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ, Bruns T, Cheung A, Li KK, Kittler C, Kumagi T, Shah H, Corbett C, Al-Harthy N, Acarsu U, Coltescu C, Tripathi D, Stallmach A, Neuberger J, Janssen HL, Hirschfield GM.
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [Abstract] [Full Text] [Related]

  • 28. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy.
    Lazaridis KN, Talwalkar JA.
    J Clin Gastroenterol; 2007 Jun; 41(5):494-500. PubMed ID: 17450033
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Treatment of cholestatic liver diseases].
    Karvonen AL.
    Duodecim; 2003 Jun; 119(6):533-9. PubMed ID: 12708340
    [No Abstract] [Full Text] [Related]

  • 32. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M, Rautiainen H, Kärkkäinen P, Karvonen AL, Nurmi H, Niemelä O.
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [Abstract] [Full Text] [Related]

  • 33. Management of autoimmune and cholestatic liver disorders.
    Krok KL, Munoz SJ.
    Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.
    Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, Dickson ER, Lindor KD.
    Hepatology; 1999 Jan; 29(1):21-6. PubMed ID: 9862844
    [Abstract] [Full Text] [Related]

  • 36. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
    ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group.
    Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
    [Abstract] [Full Text] [Related]

  • 37. [Cholestatic liver diseases: diagnosis and therapy of primary biliary cirrhosis].
    Thimme R, Opitz OG, Kreisel W.
    Dtsch Med Wochenschr; 2002 Sep 06; 127(36):1823-6. PubMed ID: 12215926
    [No Abstract] [Full Text] [Related]

  • 38. Overlap syndromes.
    Beuers U, Rust C.
    Semin Liver Dis; 2005 Aug 06; 25(3):311-20. PubMed ID: 16143946
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.